Abstract
Pharmacologic therapy represents the mainstay of treatment for heart failure in children. However, medical therapy for this population is not widely standardized. This is mainly due to the heterogeneity of potential etiologies, the specific challenge of patients with univentricular physiology and the lack of evidence-based prospective randomized clinical trials in pediatric patients. In fact, most current strategies are based largely on extrapolated data from adult studies. Although the classic drugs for heart failure i.e. diuretics, angiotensin-converting enzyme inhibitors, β-blockers and cardiac glycosides, still play a major role in the treatment of pediatric heart failure, newer alternative therapies such as levosimendan and nesiritide are increasingly utilized with promising early results. A systematic literature search of PubMed and MEDLINE databases using relevant terms was performed. All clinical trials and relevant manuscripts about the current pharmacologic treatment of heart failure in the pediatric population were reviewed. New drugs such as levosimendan and nesiritide and the treatment of single-ventricle patients were also included.
Keywords: Pediatric heart failure, diuretics, angiotensin-converting enzyme inhibitor, β-blocker, nesiritide, levosimendan, arrhythmia, anemia, digitalis, aldosterone
Current Vascular Pharmacology
Title: Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Volume: 9 Issue: 5
Author(s): Victor Bautista-Hernandez, Antonio Sanchez-Andres, Francisco Portela and Francis Fynn-Thompson
Affiliation:
Keywords: Pediatric heart failure, diuretics, angiotensin-converting enzyme inhibitor, β-blocker, nesiritide, levosimendan, arrhythmia, anemia, digitalis, aldosterone
Abstract: Pharmacologic therapy represents the mainstay of treatment for heart failure in children. However, medical therapy for this population is not widely standardized. This is mainly due to the heterogeneity of potential etiologies, the specific challenge of patients with univentricular physiology and the lack of evidence-based prospective randomized clinical trials in pediatric patients. In fact, most current strategies are based largely on extrapolated data from adult studies. Although the classic drugs for heart failure i.e. diuretics, angiotensin-converting enzyme inhibitors, β-blockers and cardiac glycosides, still play a major role in the treatment of pediatric heart failure, newer alternative therapies such as levosimendan and nesiritide are increasingly utilized with promising early results. A systematic literature search of PubMed and MEDLINE databases using relevant terms was performed. All clinical trials and relevant manuscripts about the current pharmacologic treatment of heart failure in the pediatric population were reviewed. New drugs such as levosimendan and nesiritide and the treatment of single-ventricle patients were also included.
Export Options
About this article
Cite this article as:
Bautista-Hernandez Victor, Sanchez-Andres Antonio, Portela Francisco and Fynn-Thompson Francis, Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease, Current Vascular Pharmacology 2011; 9 (5) . https://dx.doi.org/10.2174/157016111796642733
DOI https://dx.doi.org/10.2174/157016111796642733 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry Editorial: Emerging Pharmacological Strategies for the Prevention of Atherosclerotic Disease Progression
Current Drug Targets - Cardiovascular & Hematological Disorders Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Preliminary Structural Studies of the Hydrophobic Ribosomal P0 Protein from Trypanosoma cruzi, A Part of the P0/P1/P2 Complex
Protein & Peptide Letters An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Pulmonary Hypertension: Types and Treatments
Current Cardiology Reviews GRK2 at the Control Shaft of Cellular Metabolism
Current Pharmaceutical Design Effects of Ox Bile Extract on the Phospholipids and Fatty Acids Membrane Composition of Salmonella enterica Serovar Typhimurium seqA Mutant Strain
Current Chemical Biology Editorial [Hot Topic: The Evolution of Cell Therapy Towards Enhancing Vascular Regeneration in the Clinic (Guest Editors: Drew Kuraitis and Erik J. Suuronen)]
Current Vascular Pharmacology Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Resveratrol: A Therapeutic Approach to Neurodegenerative Diseases and Aging
Mini-Reviews in Organic Chemistry Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design The Journey of the Non-Vascular Relief for Migraine: From ‘Triptans’ To ‘Ditans’
Current Clinical Pharmacology Recent Updates on the Calcium-Sensing Receptor as a Drug Target
Current Medicinal Chemistry Molecular Genetics of Polycystic Ovary Syndrome: An Update
Current Molecular Medicine Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Role of Open Source Tools and Resources in Virtual Screening for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Diamidine Activity Against Trypanosomes: The State of the Art
Current Molecular Pharmacology Hepatotoxicity of Antiretroviral Drugs
Current Pharmaceutical Design Indolo[3,2-b]quinolines: Synthesis, Biological Evaluation and Structure Activity-Relationships
Mini-Reviews in Medicinal Chemistry